公开(公告)号：EP2094725A1

公开(公告)日：2009-09-02

申请号：EP07854601.7

申请日：2007-11-08

申请人： ZymoGenetics, Inc.

发明人： PRESNELL, Scott R. ,  TAFT, David W. ,  FOLEY, Kevin P.

IPC分类号： C07K14/495 ,  C07K16/22 ,  C07K14/54 ,  C07K16/24

CPC分类号： C07K14/495 ,  C07K14/54 ,  C07K16/22

摘要： Novel mammalian Ztgfβ-9 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods including antibodies and anti-idiotypic antibodies.

公开(公告)号：EP2274008B1

公开(公告)日：2014-02-26

申请号：EP09724060.0

申请日：2009-03-27

申请人： ZymoGenetics, Inc.

发明人： SIVAKUMAR, Pallavur V. ,  GILBERTSON, Debra G. ,  SNAVELY, Marshall D. ,  MABRY, George R. ,  YI, Eugene C. ,  YAO, Yue ,  PRESNELL, Scott R.

IPC分类号： A61K39/395 ,  A61P35/00 ,  C07K16/22 ,  C07K16/28

CPC分类号： C07K16/00 ,  A61K2039/505 ,  C07K16/22 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/90 ,  C07K2317/92

摘要： There is provided an isolated antibody that binds to the extracellular domain of PDGFR² and neutralizes PDGFR² activity, said antibody comprising a V L domain comprising CDRs LCDR1, LCDR2, and LCDR3 and a V H domain comprising CDRs HCDR1, HCDR2, and HCDR3, wherein: LCDR1 has the amino acid sequence shown in SEQ ID NO: 433, optionally the amino acid sequence shown in SEQ ID NO: 443; LCDR2 has the amino acid sequence shown in SEQ ID NO: 434; LCDR3 has the amino acid sequence shown in SEQ ID NO: 435, optionally the amino acid sequence shown in SEQ ID NO: 444; HCDR1 has the amino acid sequence shown in SEQ ID NO: 436, optionally the amino acid sequence shown in SEQ ID NO: 445; HCDR2 has the amino acid sequence shown in SEQ ID NO: 437; HCDR3 has an amino acid sequence selected from the group consisting of SEQ ID NOs: 438-442

公开(公告)号：EP2044118A2

公开(公告)日：2009-04-08

申请号：EP07798524.0

申请日：2007-06-13

申请人： Zymogenetics, Inc.

发明人： LEWIS, Katherine, E. ,  PRESNELL, Scott R. ,  WEST, James, W. ,  MABRY, Robert, ,  MEENGS, Brent

IPC分类号： C07K16/24 ,  C12N15/13 ,  A61K39/395 ,  A61P37/06

CPC分类号： C07K16/244 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

摘要： The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17, IL-23 via it's p19 subunit or both IL-17 and IL-23 (via p19). IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.